These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26839083)

  • 21. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study.
    Klimek L; Bachert C; Stjärne P; Dollner R; Larsen P; Haahr P; Agache I; Scadding G; Price D
    Allergy Asthma Proc; 2016 Sep; 37(5):376-86. PubMed ID: 27657521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review.
    Tantilipikorn P; Kirtsreesakul V; Bunnag C; Vangveeravong M; Thanaviratananich S; Chusakul S
    J Asthma Allergy; 2024; 17():667-679. PubMed ID: 39045291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
    Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C
    Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis.
    Debbaneh PM; Bareiss AK; Wise SK; McCoul ED
    Otolaryngol Head Neck Surg; 2019 Sep; 161(3):412-418. PubMed ID: 30961435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
    Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U
    Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel.
    Lipworth B; Newton J; Ram B; Small I; Schwarze J
    NPJ Prim Care Respir Med; 2017 Jan; 27(1):3. PubMed ID: 28115736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-Life Effectiveness of MP-AzeFlu (Dymista
    Stjärne P; Nguyen DT; Kuhl HC
    Pragmat Obs Res; 2023; 14():1-11. PubMed ID: 36628265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
    Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
    Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
    Klimek L; Bousquet J; Price D
    Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US.
    Prenner BM
    J Asthma Allergy; 2016; 9():135-43. PubMed ID: 27468241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
    Berger W; Sher E; Gawchik S; Fineman S
    Allergy Asthma Proc; 2018 Mar; 39(2):110-116. PubMed ID: 29490769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
    Meltzer EO; LaForce C; Ratner P; Price D; Ginsberg D; Carr W
    Allergy Asthma Proc; 2012; 33(4):324-32. PubMed ID: 22856633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey.
    Canonica GW; Klimek L; Acaster S; Dollner R; Kaulsay R; Lo SH; Price DB; Scadding GK; Valovirta E; Zieglmayer P
    Curr Med Res Opin; 2021 Jul; 37(7):1259-1272. PubMed ID: 33840316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study.
    Klimek L; Bachert C; Mösges R; Munzel U; Price D; Virchow JC; Wahn U; Bousquet J
    Allergy Asthma Proc; 2015; 36(1):40-7. PubMed ID: 25562555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate.
    Ridolo E; Barone A; Nicoletta F; Paoletti G; Heffler E; Malvezzi L; Canonica GW
    Expert Rev Clin Immunol; 2023 Jun; 19(6):575-584. PubMed ID: 37038974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu.
    Dollner R; Lorentz Larsen P; Dheyauldeen S; Steinsvåg S
    Allergy Rhinol (Providence); 2017 Oct; 8(3):148-156. PubMed ID: 29070272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy.
    Klimek L; Poletti SC; Sperl A; Spielhaupter M; Bardenhewer C; Mullol J; Hörmann K; Hummel T
    Int Forum Allergy Rhinol; 2017 Mar; 7(3):287-292. PubMed ID: 27888645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olopatadine/mometasone (Ryaltris) for allergic rhinitis.
    Med Lett Drugs Ther; 2023 Jan; 65(1668):12-14. PubMed ID: 36651792
    [No Abstract]   [Full Text] [Related]  

  • 39. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis.
    Scadding G; Bousquet J; Bachert C; Fokkens WJ; Hellings PW; Prokopakis E; Pfaar O; Price D
    Rhinology; 2019 Feb; 57(1):49-56. PubMed ID: 30052697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells.
    Berger WE; Bachert C; Allara R; Koltun A; Kopietz F; Maus JG; D'Addio AD
    J Asthma Allergy; 2020; 13():187-192. PubMed ID: 32547111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.